UPC: Sanofi v Amgen lands front of queue at new court

06-06-2023

Muireann Bolger

UPC: Sanofi v Amgen lands front of queue at new court

rafapress / Shutterstock

Big pharma company picks pan-European venue for next leg of global dispute | IT issues potentially behind low revocation count | Nearly half a million opt-outs registered.

The Unified Patent Court (UPC) may be less than a week old but it is already set to be the latest stage for the long-running dispute between Sanofi and Amgen concerning antibody patents.

As confirmed by lawyers to WIPR, the German division of French drugmaker Sanofi filed a revocation action against the US pharma company before the court’s central division in Munich citing patent number EP 3 666 797.

It marks a new twist in the global litigation waged between the two companies over antibody patents that wound its way to the US Supreme Court last month.


court, system, patent, UPC, Sanofi, Hogan Lovells, HGF, Simmons & Simmons, litigation, market, actions, revocation, Amgen

WIPR